Matching slides 3,551
Current window 2,311-2,340
Pages 119
Rows per page 30

Arc

2,311-2,340 of 3,551

filter-aware
23
The slide uses a scientific publication as social proof and a log-log chart to demonstrate performance scaling.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
24
D-Wave | Investor Presentation Deck | 28 slidesD-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
25
The slide uses a circular graphic to emphasize the 99% uptime metric.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
26
The slide uses a US map graphic to emphasize the 220+ US granted patents.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
27
Includes footnotes regarding YOY growth consistency and ELOC liquidity.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
28
Slide 28 of the deck.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
01
Slide 1
Includes company logo and date.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Attention1 hit
02
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Attention1 hit
03
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Attention1 hit
04
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Interest1 hit
05
TPD stands for Targeted Protein Degradation. The slide uses a three-column framework to explain their competitive advantage.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
06
The slide uses a standard pharmaceutical pipeline table format.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
07
This is a stylistic section divider slide with an abstract background.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
08
The slide uses a biological pathway diagram to illustrate the mechanism of action for a drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
09
Includes a mechanism of action diagram, a market data table, and a callout box on competitive limitations.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
10
Comparison of two distinct cohorts: Healthy Volunteers (SAD/MAD) vs. HS/AD Patient Cohort.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
11
Includes both a longitudinal line chart for IRAK4 degradation and a grouped bar chart with a supporting data table for cytokine inhibition.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
12
Includes PK/PD correlation, blood IRAK4 levels, skin exposure, and skin lesion IRAK4 reduction data.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
13
The charts show log2(fold change) for individual patients. The footnote defines the log2(fold change) values in terms of percentage decrease.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
14
Data compares 'All HS Patients' vs 'Moderate to Severe' subgroups across four metrics over 42 days.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
15
The slide includes a disclaimer that the comparison is not head-to-head and uses historical benchmarks.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
16
Data presented as mean +/- S.E. of mean; N=7 patients.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
18
The slide provides clinical safety data for the KT-474 drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
19
The slide outlines the status of a partnership with Sanofi and clinical trial timelines.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
21
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
22
Includes a table of market data and a biological pathway diagram.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
23
Includes PK/PD data and efficacy metrics in multiple T-cell lymphoma models.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
24
Includes box plots for gene expression and a tumor volume growth curve over time.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit